Citations

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

October 5, 2016
BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Read more

FOCUS: Future of Fecal Calprotectin Utility Study in Inflammatory Bowel Disease

October 3, 2016
BÜHLMANN Quantum Blue® fCAL Citation: Rosenfeld G, Greenup A-J, Round A, et al. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World Journal of Gastroenterology. 2016;22(36):8211-8218. doi:10.3748/wjg.v22.i36.8211. PMID:27688663. Highlight from this Publication "The FC test effected a change in management 51.3% of the time and receipt of the result was associated with a reduction
Read more

CAL-101, A p110delta Selective Phosphatidylinositol-3-Kinase Inhibitor for the Treatment of B-cell Malignancies, Inhibits PI3K Signaling and Cellular Viability

September 20, 2016
Flow CAST® - Kinase Inhibtion Assay Citation: Lannutti, B.J. et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011 Jan 13; 117(2): 591-594. PMID: 20959606. "We have thus described the biochemical and cellular activity of CAL-101, a selective and potent inhibitor of p110δ; such targeted
Read more

CAL-101, A p110delta Selective Phosphatidylinositol-3-Kinase Inhibitor for the Treatment of B-cell Malignancies, Inhibits PI3K Signaling and Cellular Viability

September 20, 2016
Flow CAST® - Kinase Inhibtion Assay Citation: Lannutti, B.J. et al. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011 Jan 13; 117(2): 591-594. PMID: 20959606. "We have thus described the biochemical and cellular activity of CAL-101, a selective and potent inhibitor of p110δ; such targeted
Read more